Patents by Inventor Zhongzong PAN

Zhongzong PAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-VEGF ANTIBODY AND USE THEREOF
    Publication number: 20240287168
    Abstract: Provided is an isolated antigen binding protein capable of binding to VEGF protein and/or capable of blocking binding of VEGF protein to VEGFR protein. Further provided is a use of the isolated antigen binding protein in the preparation of a drug.
    Type: Application
    Filed: February 9, 2022
    Publication date: August 29, 2024
    Inventors: Zongda Wang, Chunyin GU, Xiaodan Cao, Xiaowu Liu, Sujun Deng, Zhongzong Pan, Xueping Wang
  • ANTI-CTLA4 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20240141046
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Application
    Filed: May 18, 2023
    Publication date: May 2, 2024
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
  • ANTI-MASP-2 ANTIBODY AND USE THEREOF
    Publication number: 20240141069
    Abstract: An anti-MASP-2 antibody and use thereof. The anti-MASP-2 antibody specifically binds to a human MASP-2 protein at a KD value of about 2E-09M or less, and the anti-MASP-2 antibody specifically binds to a cynomolgus monkey MASP-2 protein at a KD value of about 2E-09M or less. Disclosed are an immunoconjugate containing the anti-MASP-2 antibody, a method for preparing the anti-MASP-2 antibody, and use of the anti-MASP-2 antibody.
    Type: Application
    Filed: June 7, 2022
    Publication date: May 2, 2024
    Inventors: Xiaowu LIU, Xiaodan CAO, Jianqiu SONG, Zongda WANG, Peipei LIU, Jianjian ZHANG, Chunyin GU, Sujun DENG, Zhongzong PAN, Xueping WANG
  • PREPARATION OF SIGLEC-15 BINDING PROTEIN AND USE THEREOF
    Publication number: 20240124576
    Abstract: The present invention provides a preparation of a Siglec-15 binding protein and the use thereof, and specifically relates to an isolated antigen-binding protein, which comprises HCDR3. Provided is the use of the antigen-binding protein in the prevention and treatment of diseases.
    Type: Application
    Filed: February 22, 2022
    Publication date: April 18, 2024
    Inventors: Xinxiu Yang, Chunyin GU, Zongda WANG, Xiaodan CAO, Xiaowu LIU, Peipei LIU, Lu YANG, Sujun DENG, Zhongzong PAN, Xueping WANG
  • GARP Protein Antibody and Use Thereof
    Publication number: 20240117034
    Abstract: Provided is an GARP protein antibody, and a cell comprising or expressing the GA RP protein antibody. The GARP protein antibody binds to human GARP/human TGF-?1 complex with a KD value of about 1.0E-12 or less. Also provided are a pharmaceutical combination comprising the GARP protein antibody and an immune checkpoint inhibitor and use thereof.
    Type: Application
    Filed: January 17, 2022
    Publication date: April 11, 2024
    Applicants: SHANGHAI JEMINCARE PHARMACEUTICAL CO., LTD., JIANGXI JEMINCARE GROUP CO., LTD.
    Inventors: Jianjian ZHANG, Zhongzong PAN, Xinxiu YANG, Xiaowu LIU, Lu YANG, Peipei LIU, Xiaodan CAO, Sujun DENG, Xueping WANG
  • ANTI-IGE ENGINEERED ANTIBODY AND APPLICATION THEREOF
    Publication number: 20230250191
    Abstract: The present application relates to an antigen-binding protein comprising amino acid mutations compared with the light and heavy chain variable region sequences of omalizumab. The antigen-binding protein of the present application is an anti-IgE engineered antibody. The present application also relates to pharmaceutical compositions comprising the antigen-binding protein, and methods thereof for alleviation or treatment of diseases associated with abnormal level of IgE.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 10, 2023
    Inventors: Sujun DENG, Chunyin GU, Xiaowu LIU, Xiaodan CAO, Peipei LIU, Jianjian ZHANG, Zhongzong PAN, Zheng XIAO, Xueping WANG, Haibing GUO
  • Anti-CTLA4 antibodies and methods of making and using the same
    Patent number: 11692036
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: July 4, 2023
    Assignee: Adagene Inc.
    Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
  • Anti-CTLA4 antibodies and methods of making and using the same
    Patent number: 11359016
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: June 14, 2022
    Assignee: ADAGENE INC.
    Inventors: Peter Peizhi Luo, Fangyong Du, Zhongzong Pan, Guizhong Liu
  • ANTI-CTLA4 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20210206855
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Application
    Filed: February 2, 2019
    Publication date: July 8, 2021
    Applicant: Adagene Inc.
    Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU
  • ANTI-CTLA4 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20190241662
    Abstract: Provided herein are cross-reactive antibodies (or antigen binding fragments thereof) that bind to human CTLA4, activatable antibodies that bind to human CTLA4, nucleic acid molecules encoding the same, pharmaceutical compositions thereof, and methods of their therapeutic use (e.g., for treatment of cancer).
    Type: Application
    Filed: February 1, 2019
    Publication date: August 8, 2019
    Applicant: ADAGENE INC.
    Inventors: Peter Peizhi LUO, Fangyong DU, Zhongzong PAN, Guizhong LIU